Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy

Urology

Volumn 70, Issue 3, 2007, Pages 527-531

  Daskivich, Timothy J ^a,b   Regan, Meredith M ^a,b   Oh, William K ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; HEMOGLOBIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS;

EID: 34648817446     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.04.035     Document Type: Article

References (8)

1. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
2. Hanks G.E., Hanlon A.L., Lee W.R., et al. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34 (1996) 549-553
3. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
4. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
5. D'Amico A.V., Moul J., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
6. Shulman M.J., and Benaim E.A. The natural history of androgen independent prostate cancer. J Urol 172 (2004) 141-145
7. D'Amico A.V., Moul J., Carroll P.R., et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 173 (2005) 1572-1576
8. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467